Complete response rate was 37%, and post-hoc end point of objective response rate was 89%. HealthDay News — Patients with advanced desmoplastic melanoma have high response to single-agent ...

ORLANDO -- Exceedingly high response rates were seen with pembrolizumab (Keytruda) in patients with unresectable metastatic desmoplastic melanoma, according to results from the SWOG S1512 phase II ...

Please provide your email address to receive an email when new articles are posted on . Neoadjuvant pembrolizumab induced pathologic complete response in 71% of patients with desmoplastic melanoma.

Seventy-one percent of patients had pathological complete response; 7% experienced grade 3 treatment-related adverse events. HealthDay News — For patients with desmoplastic melanoma, neoadjuvant ...

Tumors from desmoplastic melanoma, a rare cancer most commonly found on the head or neck, can often be shrunk significantly before surgery by an immunotherapy known as PD-1 blockade, a result that may ...

Desmoplastic melanoma (DM) is a distinct and uncommon variant of cutaneous melanoma, distinguished by its abundant fibrous stroma and spindle-shaped melanocytes. Recent investigations have underscored ...

Close to 90 percent of patients with unresectable (inoperable) desmoplastic melanoma, a rare form of skin cancer, saw their cancer improve after treatment with the immunotherapy drug pembrolizumab in ...

COLUMBUS, Ohio — A national clinical trial conducted by Ohio State University researchers has found that patients with a rare form of skin cancer called desmoplastic melanoma had a dramatic response ...

Melanoma 3.0T—Tech Innovations, New Targeted Therapies, and T-Cell Breakthroughs Not all melanomas are the same. They differ in presentation, mutational status, and behavior. Desmoplastic melanoma (DM ...

Desmoplastic melanoma, an often deeply invasive disease occurring in older adults, showed a uniquely favorable response to neoadjuvant pembrolizumab (Keytruda) in a small study, with most patients ...

Randomized Trial of Radiotherapy Versus Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy in Patients With American Joint Committee on Cancer/International Union Against Cancer Stage III ...